File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Efficacy of 0.01% atropine for myopia control in a randomized, placebo-controlled trial depends on baseline electroretinal response

TitleEfficacy of 0.01% atropine for myopia control in a randomized, placebo-controlled trial depends on baseline electroretinal response
Authors
Issue Date2022
Citation
Scientific Reports, 2022, v. 12 How to Cite?
AbstractThis study aimed to evaluate the efficacy of 18-month 0.01% atropine in 61 myopic children (aged 7-10) and the relationship with central retinal response (by multifocal electroretinogram [mfERG]) in a double-masked randomized placebo-controlled clinical trial. Global-flash mfERG was measured at baseline, while cycloplegic spherical equivalent refraction (SER) and axial length (AL) were measured at baseline and at 6-month intervals. Annualized change in SER and AL were compared between atropine and control groups, and the relationships with baseline mfERG were evaluated. Changes in SER (-0.70 ± 0.39D vs. -0.66 ± 0.41D, p = 0.63) and AL (0.32 ± 0.16 mm vs. 0.30 ± 0.22 mm, p = 0.52) were similar in atropine and control groups. Interestingly, in the placebo group, mfERG amplitude was negatively correlated with axial elongation (Rp = -0.44, p = 0.03) as in our previous study. However, in the atropine group, an opposite trend was observed that axial elongation was positively correlated with mfERG amplitude (Ra = 0.37, p = 0.04). Annualized myopia progression demonstrated similar opposite effect between atropine and placebo groups but did not reach statistical significance. An ERG screening protocol may be warranted to identify suitable candidates to reduce the likelihood of an unfavorable treatment response by 0.01% atropine.
Persistent Identifierhttp://hdl.handle.net/10722/319526
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChan, HHL-
dc.contributor.authorChoi, KY-
dc.contributor.authorNg, LKA-
dc.contributor.authorChoy, NKB-
dc.contributor.authorChan, JCH-
dc.contributor.authorChan, SSH-
dc.contributor.authorLi, SZC-
dc.contributor.authorYu, WY-
dc.date.accessioned2022-10-14T05:14:55Z-
dc.date.available2022-10-14T05:14:55Z-
dc.date.issued2022-
dc.identifier.citationScientific Reports, 2022, v. 12-
dc.identifier.urihttp://hdl.handle.net/10722/319526-
dc.description.abstractThis study aimed to evaluate the efficacy of 18-month 0.01% atropine in 61 myopic children (aged 7-10) and the relationship with central retinal response (by multifocal electroretinogram [mfERG]) in a double-masked randomized placebo-controlled clinical trial. Global-flash mfERG was measured at baseline, while cycloplegic spherical equivalent refraction (SER) and axial length (AL) were measured at baseline and at 6-month intervals. Annualized change in SER and AL were compared between atropine and control groups, and the relationships with baseline mfERG were evaluated. Changes in SER (-0.70 ± 0.39D vs. -0.66 ± 0.41D, p = 0.63) and AL (0.32 ± 0.16 mm vs. 0.30 ± 0.22 mm, p = 0.52) were similar in atropine and control groups. Interestingly, in the placebo group, mfERG amplitude was negatively correlated with axial elongation (Rp = -0.44, p = 0.03) as in our previous study. However, in the atropine group, an opposite trend was observed that axial elongation was positively correlated with mfERG amplitude (Ra = 0.37, p = 0.04). Annualized myopia progression demonstrated similar opposite effect between atropine and placebo groups but did not reach statistical significance. An ERG screening protocol may be warranted to identify suitable candidates to reduce the likelihood of an unfavorable treatment response by 0.01% atropine.-
dc.languageeng-
dc.relation.ispartofScientific Reports-
dc.titleEfficacy of 0.01% atropine for myopia control in a randomized, placebo-controlled trial depends on baseline electroretinal response-
dc.typeArticle-
dc.identifier.emailChoy, NKB: bnkchoy@hku.hk-
dc.identifier.emailChan, JCH: jonochan@hku.hk-
dc.identifier.authorityNg, LKA=rp01842-
dc.identifier.authorityChoy, NKB=rp01795-
dc.identifier.authorityChan, JCH=rp02113-
dc.identifier.doi10.1038/s41598-022-15686-6-
dc.identifier.hkuros339605-
dc.identifier.volume12-
dc.identifier.isiWOS:000822436100027-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats